Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Stem Cell Reports|July 6, 2026
Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectationsChengyuan Press, Kevin D'Amour, Nicholas Mamrak, et al.
Cell Metabolism|November 7, 2007
The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscleBrian A Clarke, Doreen Drujan, Monte S Willis, et al.
Skeletal Muscle|October 13, 2015
Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged miceEsther Latres, Jeffrey Pangilinan, Lawrence Miloscio, et al.
Diabetes|February 13, 2024
Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 DiabetesEsther Latres, Carla J Greenbaum, Maria L Oyaski, et al.
The Lancet. Diabetes & Endocrinology|November 6, 2023
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysisPeter N Taylor, Kimberly S Collins, Anna Lam, et al.
Nature Communications|April 29, 2017
Activin A more prominently regulates muscle mass in primates than does GDF8Esther Latres, Jason Mastaitis, Wen Fury, et al.
Frontiers in Immunology|October 16, 2024
TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trialCassandra Bazile, Magdy M Abdel Malik, Courtney Ackeifi, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 18, 2018
Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshopMichael R Rickels, Peter G Stock, Eelco J P de Koning, et al.
Transplantation|March 13, 2018
Defining Outcomes for β-cell Replacement Therapy in the Treatment of Diabetes: A Consensus Report on the Igls Criteria From the IPITA/EPITA Opinion Leaders WorkshopMichael R Rickels, Peter G Stock, Eelco J P de Koning, et al.
Nature Reviews. Endocrinology|September 3, 2024
Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road aheadAlessandro Grattoni, Gregory Korbutt, Alice A Tomei, et al.
Pageof 3